Se connecter Inscription gratuite

Last updated: 15 June 2019 at 3:17am EST

William McClellan Net Worth




The estimated Net Worth of William Estate Of Edward W.... is at least $25.2 million dollars as of 1 June 2016. Mr. W owns over 1,100,000 units of Reata Pharmaceuticals Inc stock worth over $24,647,480 and over the last 8 years he sold RETA stock worth over $0. In addition, he makes $599,306 as Independent Director at Reata Pharmaceuticals Inc.

Mr. McClellan RETA stock SEC Form 4 insiders trading

William has made over 1 trades of the Reata Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 1,100,000 units of RETA stock worth $12,100,000 on 1 June 2016.

The largest trade he's ever made was buying 1,100,000 units of Reata Pharmaceuticals Inc stock on 1 June 2016 worth over $12,100,000. On average, William trades about 1,100,000 units every 0 days since 2016. As of 1 June 2016 he still owns at least 143,000 units of Reata Pharmaceuticals Inc stock.

You can see the complete history of Mr. W stock trades at the bottom of the page.





William McClellan biography

William D. McClellan Jr., CPA serves as Independent Director of the Company. He is an independent Director of Reata Pharmaceuticals Inc. Mr. McClellan, Jr. has served as the Chief Financial Officer of Aerin Medical Inc. since January 2018. Mr. McClellan, Jr. is a financial management consultant to healthcare and life sciences companies, serving as the managing member of Goodwater Consulting, LLC since March 2017. From June 2004 until June 2016, Mr. McClellan, Jr. was the Chief Financial Officer and Executive Vice President, Finance at On-X Life Technologies Holdings, Inc. Prior to June 2004, Mr. McClellan, Jr. held financial and accounting positions at various healthcare and other companies and was a certified public accountant serving as an auditor with PricewaterhouseCoopers for nine years. He currently serves on the board of directors of Apollo Endosurgery, Inc., a publicly-traded company, and chairs its audit committee. Mr. McClellan, Jr. received a B.B.A. in accounting from Abilene Christian University and is a certified public accountant. Our Board believes that Mr. McClellan, Jr. is qualified to serve on our Board due to his extensive experience in finance and accounting roles in the healthcare and life sciences industry and in serving as a certified public accountant at a large public accounting firm.

What is the salary of William McClellan?

As the Independent Director of Reata Pharmaceuticals Inc, the total compensation of William McClellan at Reata Pharmaceuticals Inc is $599,306. There are 11 executives at Reata Pharmaceuticals Inc getting paid more, with Manmeet Soni having the highest compensation of $12,612,200.



How old is William McClellan?

William McClellan is 60, he's been the Independent Director of Reata Pharmaceuticals Inc since 2017. There are 5 older and 10 younger executives at Reata Pharmaceuticals Inc. The oldest executive at Reata Pharmaceuticals Inc is Michael D. Wortley, 73, who is the Exec. VP & Chief Legal Officer.

Insiders trading at Reata Pharmaceuticals Inc

Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy et Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.



What does Reata Pharmaceuticals Inc do?

reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.



What does Reata Pharmaceuticals Inc's logo look like?

Reata Pharmaceuticals Inc logo

Complete history of Mr. W stock trades at Reata Pharmaceuticals Inc

Date
#
Société
 Initié
Trans.
Transaction
 Actions Prix par action Prix ​​total Actions après Source
1 Jun 2016 RETA Reata Pharmaceuticals Inc William Estate Of Edward W....
Acheter 1,100,000 $11.00 $12,100,000
1 Jun 2016
143,000 ↗


Reata Pharmaceuticals Inc executives and stock owners

Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include: